Pharmafile Logo

Article: War in the Blood – The battle takes shape in the burgeoning European oncology CAR-T market access space

July 13, 2023 | Market Access 

Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum’s Deep Dive.

- PMLiVEWith the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers of these exciting, in theory, one-shot personalised therapies.

I have a vivid memory of watching War in the Blood, a 2019 feature-length BBC documentary about CAR-T cell therapy and the potentially revolutionary impact on the landscape of cancer treatment. The filmmakers followed two leukaemia patients in first-in-human trials in the UK. CAR-T was showcased as their only hope and a way to re-programme the immune system to kill cancers. As with any clinical trial, questions arose. In this case, key questions centred around the long-term safety and effectiveness of the personalised CAR-T, due to its potential curative intent.

As more CAR-Ts have obtained marketing authorisation in the intervening years, similar questions have also been on the minds of payers and policymakers making decisions about how – and in which patient populations – to pay for this new modality, whose upfront cost and theoretically one-time administration is difficult to assess in the same way as traditional drugs.

In this article for pharmaphorum’s Oncology Deep Dive, Research Partnership reviews the market access opportunities and challenges encountered by CAR-Ts commercialised in the EU-4 and the UK (see Tables 1 and 2). To complement our review, we reached out to 12 payers in our network with advanced therapy expertise from across the UK, France, Germany, Spain, and Italy. We discuss their feedback and the ramifications below. We also share select findings from our new syndicated tool Access CGT, a cell and gene therapy analogue access and policy tracker.

Find out more here

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Webcast: Virtual Q&A session – The future of digital health

In this webcast, Senior Director, Richard Head and Director of The Medical Futurist, Dr. Bertalan Mesko host a live virtual Q&A discussion about the future of digital health.

Research Partnership is on the rise

Research Partnership ranks 12th in fastest growing UK market research agency league  tables

What does the future hold for Light-chain Amyloidosis?

Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...

Webcast: Securing a future for telehealth with immersive market research insights

Research Partnership investigate the current landscape, the challenges to adoption and the future for telehealth.

Breaking the silence: It’s time to talk about the menopause

Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.

News:

Senior Analytics Specialist joins Research Partnership

Article:

All change – how untangling human behaviour can encourage better health

Webcast:

Understanding changing digital behaviours: Insights needed for an effective omnichannel strategy

News:

Therapy Watch COVID-19 tracker

Events:

Patient Centricity and Engagement Conference 2021